How to maximize and optimize clinical research participation remains an unresolved issue in clinical research. There is no one-size-fits-all approach to cancer clinical research, and similar to the concept of precision oncology, there may be a role for personalized clinical research. We have focused on this topic in the given editorial.Precision medicine has laid the foundation for personalized approaches to both prevent and cure many cancers. Similar principles should be applied to optimize clinical research participation for childhood cancer survivors (CCS) that ultimately improves their clinical care and outcomes.
With US survival rates approaching 80% for childhood cancer, it is estimated that in 2020, there will be more than 500,000 survivors of childhood cancer.4 More than 70% of these CCS have long-term complications or chronic conditions (termed late effects).5 Despite the significant risk for adverse health effects, only 18% report receiving survivor-focused care to either prevent these late effects or to provide necessary surveillance testing for early detection.To promote precision clinical research, our CCS program engaged in a program evaluation effort to examine our survivors’ and their parents’/caregivers’ preferences for research participation.
We can say that personalised clinic research finds a very big role in this field.
